Research programme: anti-CD20 monoclonal antibody - SynthonAlternative Names: BLX-301
Latest Information Update: 10 May 2012
At a glance
- Originator Biolex
- Developer Synthon
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical B cell lymphoma